Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 plus cetuximab in KRAS p.G12C-mutant advanced colorectal and related gastrointestinal cancers
CTR20220015Phase 2Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glecirasib, cetuximab in colorectal cancer (CRC), small bowel cancer, appendiceal cancer, sponsored by Jacobio Pharmaceuticals. Started Feb 2022; status: active.
02
Drugs
glecirasibcetuximab
03
Conditions
colorectal cancer (CRC)small bowel cancerappendiceal cancer
Beyond the preview
Go deeper on CTR20220015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220015.